Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer.
EgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. Larval protoscoleces, whic...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6118354?pdf=render |
id |
doaj-407c7ae2633e4bde9cd3aace055902f5 |
---|---|
record_format |
Article |
spelling |
doaj-407c7ae2633e4bde9cd3aace055902f52020-11-24T20:41:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01138e020043310.1371/journal.pone.0200433Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer.Shiwanthi L RanasingheGlen M BoyleKatja FischerJeremy PotriquetJason P MulvennaDonald P McManusEgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. Larval protoscoleces, which develop within the hydatid cyst, have been shown to possess anti-cancer properties, although the precise molecules involved have not been identified. We show that recombinant EgKI-1 inhibits the growth and migration of a range of human cancers including breast, melanoma and cervical cancer cell lines in a dose-dependent manner in vitro without affecting normal cell growth. Furthermore, EgKI-1 treatment arrested the cancer cell growth by disrupting the cell cycle and induced apoptosis of cancer cells in vitro. An in vivo model of triple negative breast cancer (MDA-MB-231) in BALB/c nude mice showed significant tumor growth reduction in EgKI-1-treated mice compared with controls. These findings indicate that EgKI-1 shows promise for future development as an anti-cancer therapeutic.http://europepmc.org/articles/PMC6118354?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shiwanthi L Ranasinghe Glen M Boyle Katja Fischer Jeremy Potriquet Jason P Mulvenna Donald P McManus |
spellingShingle |
Shiwanthi L Ranasinghe Glen M Boyle Katja Fischer Jeremy Potriquet Jason P Mulvenna Donald P McManus Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. PLoS ONE |
author_facet |
Shiwanthi L Ranasinghe Glen M Boyle Katja Fischer Jeremy Potriquet Jason P Mulvenna Donald P McManus |
author_sort |
Shiwanthi L Ranasinghe |
title |
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. |
title_short |
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. |
title_full |
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. |
title_fullStr |
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. |
title_full_unstemmed |
Kunitz type protease inhibitor EgKI-1 from the canine tapeworm Echinococcus granulosus as a promising therapeutic against breast cancer. |
title_sort |
kunitz type protease inhibitor egki-1 from the canine tapeworm echinococcus granulosus as a promising therapeutic against breast cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
EgKI-1, a member of the Kunitz type protease inhibitor family, is highly expressed by the oncosphere of the canine tapeworm Echinococcus granulosus, the stage that is infectious to humans and ungulates, giving rise to a hydatid cyst localized to the liver and other organs. Larval protoscoleces, which develop within the hydatid cyst, have been shown to possess anti-cancer properties, although the precise molecules involved have not been identified. We show that recombinant EgKI-1 inhibits the growth and migration of a range of human cancers including breast, melanoma and cervical cancer cell lines in a dose-dependent manner in vitro without affecting normal cell growth. Furthermore, EgKI-1 treatment arrested the cancer cell growth by disrupting the cell cycle and induced apoptosis of cancer cells in vitro. An in vivo model of triple negative breast cancer (MDA-MB-231) in BALB/c nude mice showed significant tumor growth reduction in EgKI-1-treated mice compared with controls. These findings indicate that EgKI-1 shows promise for future development as an anti-cancer therapeutic. |
url |
http://europepmc.org/articles/PMC6118354?pdf=render |
work_keys_str_mv |
AT shiwanthilranasinghe kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer AT glenmboyle kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer AT katjafischer kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer AT jeremypotriquet kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer AT jasonpmulvenna kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer AT donaldpmcmanus kunitztypeproteaseinhibitoregki1fromthecaninetapewormechinococcusgranulosusasapromisingtherapeuticagainstbreastcancer |
_version_ |
1716824351349669888 |